Rates of negative MRD and survival outcomes. Assessment of patients in clinical subgroups (A) and mutational subgroups (B) of AML treated with DEC10-VEN; outcomes according to MRD status at 2 months, including competing risk analysis for cumulative incidence of relapse (CIR) with death as a competing event (C), RFS (D), EFS (E), and OS (F). CG, cytogenetics; NR, not reached; pts, patients; sAML, secondary AML from antecedent hematologic disorder; t-AML, therapy-related AML.